Accelrys Announces Inaugural NanoBiology Initiative Meeting and First Initiative Member; Meeting Will Launch International Collaboration to Develop NanoBiology Modeling and Workflow Solutions.

SAN DIEGO -- Accelrys, Inc. (NASDAQ:ACCL), a leading provider of scientific software and workflow solutions, today announced its NanoBiology Initiative's first member organization, Italy's University of Trieste. The Accelrys NanoBiology Initiative is an international collaborative framework to develop the scientific solutions that address critical challenges in drug delivery, diagnostics and bioengineering through multi-scale modeling. A leader in the computational analysis of nanomaterials for cancer detection, the University of Trieste will join Accelrys scientists, Initiative members, and technical advisors at the NanoBiology Initiative's inaugural meeting being held on September 25th at the Sheraton Commander in Cambridge, Massachusetts.

For event registration and additional information, please visit: http://www.accelrys.com/info/initiatives/nanobio/ initiative_meetings/sept2006.html

"The Accelrys NanoBiology Initiative was expressly designed to engage the world's foremost scientists across academia, government and industry to identify the immediate needs in effective next-generation nanomaterials design for medical applications and to develop the modeling, simulation and data management solutions that address those needs," said Mark Emkjer, CEO and President of Accelrys. "An invaluable addition to the Initiative, the University of Trieste, is the first of many member organizations that will guide the development of - and ultimately be among the earliest to benefit from - Accelrys' resulting portfolio of nanobiology solutions."

"The rapid convergence of nanotechnology and biotechnology has generated a need for design tools that can incorporate sufficiently detailed models of the nanoscale molecular phenomena with the larger-scale interaction and performance integral to their inclusion in biomedical devices," said Sabrina Pricl, Professor in the University of Trieste's Department of Chemical, Environmental and Raw Materials Engineering. "Currently, there is no unique software available that performs that multi-scale task, a critical need that I look forward to help solving through our participation in the Accelrys NanoBiology Initiative."

The NanoBiology Initiative's first meeting will explore how multi-scale modeling will enable the design of material properties and other factors critical to biomedical research and development. Attendees will gain the opportunity to collaborate with their peers in guiding the Initiative, learn directly from Accelrys' team of technical experts, try Accelrys' newly developed software for nanotechnology and nanobiology firsthand, and hear about the latest in nanomaterials computational design from biomedical luminaries including:

--Institute Professor Robert Langer, Massachusetts Institute of Technology - delivering an overview of cutting-edge advances in drug delivery and tissue engineering, two particularly promising application areas for computational modeling and simulation.

--Professor Mauro Ferrari, University of Texas Health Science Center - discussing the role of multi-scale modeling in effectively advancing nanotechnology for medicine.

--Professor Sabrina Pricl, University of Trieste - presenting specific opportunities and critical success factors for taking nanomaterials from computation through real world biomedical application. Topics include: drug design and resistance prediction.

--Dr. Selena Chan, Senior Staff Scientist and Manager of Applications Development at Intel, will discuss combining nanotechnology with biology and medicine.

--Dr. Reinier Akkermans, Accelrys - covering challenges and emerging solutions for the multi-scale simulation of soft nanomaterials and nanostructures including membranes and polymeric nanoparticles.

--Dr. Michael Doyle, Accelrys - introducing Accelrys' Pipeline Pilot environment and how its capabilities for data management and modeling make it a powerful tool for multi-scale modeling and data analysis in nanobiology.

About Accelrys

Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, modeling, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design, as well as drug discovery and development. SciTegic, Inc., a wholly owned subsidiary of Accelrys, has pioneered a new technology platform called "data pipelining" to process research discovery data with unprecedented flexibility. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements, including statements relating to the NanoBiology Initiative and products resulting therefrom, are subject to risks and uncertainties including, but not limited to, the risks that the initiative will not be successful and that it will not result in the timely or successful development or commercialization of software, as well as risks relating to market acceptance or demand relating to the initiative or software, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe harbor for forward-looking statements contained in the Act and, disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.